Alogliptin C₁₈H₂₁N₅O₂
Active ingredient description
Alogliptin is a potent and highly selective inhibitor of DPP-4, >10,000-fold more selective for DPP-4 than other related enzymes including DPP-8 and DPP-9. Alogliptin improves glycaemic control via a glucose-dependent mechanism, whereby insulin release is enhanced and glucagon levels are suppressed when glucose levels are high.
Medicine classification
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Product monographs
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
Structural formula
Chemical formula: C₁₈H₂₁N₅O₂
Molecular mass: 339.392 g/mol
External identifiers
Medicines
Alogliptin is an active ingredient of these brands:
United States (US)
Australia (AU)
- NESINA as ALOGLIPTIN BENZOATE
- (combination) NESINA MET
Brazil (BR)
- NESINA as ALOGLIPTIN BENZOATE
- (combination) NESINA MET
- (combination) NESINA PIO as ALOGLIPTIN BENZOATE
Hong Kong (HK)
- NESINA as ALOGLIPTIN BENZOATE
- (combination) NESINA MET
- (combination) OSENI as ALOGLIPTIN BENZOATE
Japan (JP)
Mexico (MX)
- (combination) INCRESINA P
Singapore (SG)
- NESINA as ALOGLIPTIN BENZOATE
Turkey (TR)
- VIPIDIA as ALOGLIPTIN BENZOATE
While we strive to include the brand names of medicines across all countries, our index remains incomplete. Therefore, it is possible that this medicine may also be marketed under different names in other countries.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.